| Symbol | AYTU |
|---|---|
| Name | AYTU BIOPHARMA, INC |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Pharmaceutical Preparations |
| Address | 7900 E. UNION AVENUE, DENVER, CO 80237 |
| Telephone | (720) 437-6580 |
| Fax | — |
| — | |
| Website | https://www.aytubio.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001385818 |
| Description | Aytu BioPharma is a pharmaceutical company focused on commercializing novel therapeutics. The companys prescription products include Adzenys XR-ODT(R) (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) and Cotempla XR-ODT(R) (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of attention deficit hyperactivity disorder (ADHD), Karbinal(R) ER (carbinoxamine maleate), an extended-release antihistamine suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor(R) and Tri-Vi-Flor(R), two complementary fluoride-based prescription vitamin product lines available in various formulations for infants and children with fluoride deficiency. Additional info from NASDAQ: |
Aytu BioPharma to Present at the Planet MicroCap Las Vegas 2026 Investor Conference on June 17, 2026
Read moreAytu BioPharma to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
Read moreAytu BioPharma Reports Fiscal 2026 Third Quarter Operational and Financial Results
Read more(30% Negative) AYTU BIOPHARMA, INC (AYTU) Reports Q2 2026 Financial Results
Read moreAytu BioPharma to Report Fiscal 2026 Third Quarter Operational and Financial Results on May 13, 2026
Read moreNew Form SCHEDULE 13G/A - AYTU BIOPHARMA, INC <b>Filed:</b> 2026-02-17 <b>AccNo:</b> 0000935836-26-000109 <b>Size:</b> 12 KB
Read moreNew Form SCHEDULE 13G/A - AYTU BIOPHARMA, INC <b>Filed:</b> 2026-02-13 <b>AccNo:</b> 0001535264-26-000010 <b>Size:</b> 8 KB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT02839447 | A Clinical Evaluation of Semen Quality Using the MiOXSYS™ System 2.0 | — | Male Infertility | Withdrawn | 2025-09-01 | 2026-04-01 | ClinicalTrials.gov |
| NCT05463679 | Investigate Efficacy, Safety, and Pharmacokinetics of Enzastaurin for the Preve… | Phase3 | Vascular Ehlers-Danlos Syndrome | Suspended | 2025-01-01 | 2027-03-01 | ClinicalTrials.gov |
| NCT05166915 | Respiratory COVID-19: A Randomized, Sham-Controlled Study | Na | COVID-19 Pneumonia | Withdrawn | 2022-10-01 | 2022-12-01 | ClinicalTrials.gov |
| NCT04572399 | UVA Light Device to Treat COVID-19 | Na | Coronavirus | Completed | 2020-10-30 | 2020-12-28 | ClinicalTrials.gov |
| NCT07169162 | ADZENYS XR-ODT™ in Children (4 to <6 Years) Diagnosed With Attention-deficit/Hy… | Phase4 | Attention Deficit Hyperactivity Disorder | Withdrawn | 2019-05-01 | 2025-09-05 | ClinicalTrials.gov |
| NCT04758260 | Influence of the Antioxidant Treatment in the Oxidant-reduction Potential in Se… | Na | Compare the sORP Rate in Sperm Samples, Obtained by the Mioxsys System, Before and After 2.5 Months Antioxidant Men Supplements Treatment (Fertybiotic Man) | Withdrawn | 2019-02-12 | 2021-02-12 | ClinicalTrials.gov |
| NCT02786459 | Detection and Localization of Carcinoma Using High Resolution Transrectal Imagi… | Na | Prostate Cancer | Completed | 2016-04-01 | 2019-04-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| UV Light Treatment | Drug | Approved | Coronavirus | COMPLETED | NCT04572399 |
| SPECT-CT | Other | Approved | Prostate Cancer | COMPLETED | NCT02786459 |
| Magnetic Resonance Imaging | Other | Approved | Prostate Cancer | COMPLETED | NCT02786459 |
| ProxiScan | Other | Approved | Prostate Cancer | COMPLETED | NCT02786459 |
| Antioxidant | Other | Approved | Compare the sORP Rate in Sperm Samples, Obtained by the Mioxsys System, Before and After 2.5 Months Antioxidant Men Supplements Treatment (Fertybiotic Man) | WITHDRAWN | NCT04758260 |
| Sham Control Catheter | Other | Approved | COVID-19 Pneumonia | WITHDRAWN | NCT05166915 |
| UVA Light Emitting Catheter | Other | Approved | COVID-19 Pneumonia | WITHDRAWN | NCT05166915 |
| Placebo | Other | Phase PHASE3 | Vascular Ehlers-Danlos Syndrome | SUSPENDED | NCT05463679 |
| Enzastaurin | Other | Phase PHASE3 | Vascular Ehlers-Danlos Syndrome | SUSPENDED | NCT05463679 |
| Diagnostic | Other | Preclinical | Male Infertility | WITHDRAWN | NCT02839447 |
| Placebo Oral Tablet | Other | Phase PHASE4 | Attention Deficit Hyperactivity Disorder | WITHDRAWN | NCT07169162 |
| ADZENYS XR-ODT | Other | Phase PHASE4 | Attention Deficit Hyperactivity Disorder | WITHDRAWN | NCT07169162 |
| Placebo Oral Tablet | DRUG | Phase PHASE4 | Attention Deficit Hyperactivity Disorder | WITHDRAWN | NCT07169162 |
| ADZENYS XR-ODT | DRUG | Phase PHASE4 | Attention Deficit Hyperactivity Disorder | WITHDRAWN | NCT07169162 |
| Placebo | DRUG | Phase PHASE3 | Vascular Ehlers-Danlos Syndrome | SUSPENDED | NCT05463679 |
| Enzastaurin | DRUG | Phase PHASE3 | Vascular Ehlers-Danlos Syndrome | SUSPENDED | NCT05463679 |
| Sham Control Catheter | DEVICE | Approved | COVID-19 Pneumonia | WITHDRAWN | NCT05166915 |
| UVA Light Emitting Catheter | DEVICE | Approved | COVID-19 Pneumonia | WITHDRAWN | NCT05166915 |
| UV Light Treatment | DEVICE | Approved | Coronavirus | COMPLETED | NCT04572399 |
| SPECT-CT | DEVICE | Approved | Prostate Cancer | COMPLETED | NCT02786459 |
| Magnetic Resonance Imaging | DEVICE | Approved | Prostate Cancer | COMPLETED | NCT02786459 |
| ProxiScan | DEVICE | Approved | Prostate Cancer | COMPLETED | NCT02786459 |